Psilocybin
Johns Hopkins Study Shows Psilocybin Effective for a Year
The article Johns Hopkins Study Shows Psilocybin Effective for a Year was originally published on Microdose.
A new study by Johns Hopkins Medicine shows…

The article Johns Hopkins Study Shows Psilocybin Effective for a Year was originally published on Microdose.
A new study by Johns Hopkins Medicine shows that the antidepressant effects of psilocybin (with psychotherapy) can last at least a year after treatment.
This was a follow-up to previous studies by Johns that showed positive results for major depressive disorder symptoms for up to a month. The new study shows that these impressive results can last much longer — positive news for both the industry and patients in need.
From the Johns Hopkins website:
“Our findings add to evidence that, under carefully controlled conditions, this is a promising therapeutic approach that can lead to significant and durable improvements in depression,” says Natalie Gukasyan, M.D.
Participants had stable rates of response to the treatment and remission of symptoms throughout the follow-up period, with 58% remission at 12 months.
“Psilocybin not only produces significant and immediate effects, it also has a long duration, which suggests that it may be a uniquely useful new treatment for depression,” says Roland Griffiths, founding director of the Johns Hopkins Center for Psychedelic and Consciousness Research.
“Compared to standard antidepressants, which must be taken for long stretches of time, psilocybin has the potential to enduringly relieve the symptoms of depression with one or two treatments.”
The new study was published on Feb. 15, 2022, in the Journal of Psychopharmacology.
Interested in more on psilocybin research? See New Study Shows Mushrooms Can Reverse Alcohol Brain Damage and New Study: Microdosing Related to Lower Anxiety and Depression
psilocybin psychedelic microdosing major depressive disorder psychotherapy depressive disorder depression antidepressant anxiety research
-
Psilocybin18 hours ago
The Psychedelics Megatrend Is an Inevitable Boom
-
Public Companies16 hours ago
MindMed Expenses Rise As Company Files $100 Million Offering
-
Markets & Investing18 hours ago
Microdose’s Deal Board Helps Democratize Psychedelic Investing
-
Psilocybin12 hours ago
Can Ibogaine Treat Emotional Trauma?
-
Psilocybin19 hours ago
Optimi Health acquires catalog of psychedelic and functional mushroom genetics
-
Psilocybin12 hours ago
Journey Colab Looks to Mescaline for Treating Alcohol Use Disorder